400th Patient Enrolled in Intrinsic Therapeutics Spine Device Trial

Intrinsic Therapeutics has enrolled the 400th patient in a level 1, prospective, randomized, multi-center clinical trial to evaluate the Barricaid Prosthesis for lumbar discectomy patients.

Advertisement

 

The study is being conducted in Germany, Switzerland, Austria and The Benelux to treat patients with sciatica. The project studies the safety and effectiveness of the Barricaid device and investigates clinical and radiographic information related to disc degeneration.

 

 

More Articles on Orthopedic and Spine Devices:
Lanx Publishes Favorable Study for ASPEN Minimally Invasive Spinal Fusion Device
Integra LifeSciences Receives FDA Clearance for Titan Reverse Shoulder System
DJO Global Posts $20.6M Net Loss in Q2

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.